OncoKB™ is a comprehensive precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that annotates the oncogenic effects and clinical actionability of somatic alterations in cancer. OncoKB™ assigns evidence-based levels of clinical actionability to individual mutational events in a tumor type-specific context. As of 2024, OncoKB™ contains annotations for >7500 alterations in >850 cancer-associated genes.
In October 2021, OncoKB™ became partially FDA recognized as a public human genetic variant database to support clinical validity for genetic and genomic-based in vitro diagnostics.
As of 2024, OncoKB™ has published two articles that outline the precision oncology cancer therapy landscape and detail how OncoKB™ integrates within this landscape:
• Suehnholz, et al. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discovery, 2023.
• Chakravarty, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017.
OncoKB™ offers licenses for academic, commercial and hospital use, with which users can programmatically access the web API. Please visit our website for inquiries regarding licenses.
Company Details
- Employees
- 6
- Address
- New York, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.oncokb.org/
- Keywords
- Precision Oncology, Cancer Genes, Targeted Therapy, Genomic Alterations, Cancer Biomarkers.
- HQ
- New York, NY
Oncokb Questions
Oncokb's website is https://www.oncokb.org/
Oncokb's LinkedIn profile is https://www.linkedin.com/company/oncokb
Oncokb has
6 employees.
View email and phone details for 6
employees at Oncokb.
Oncokb's industry is
Biotechnology Research
Oncokb's categories are Biotechnology Research
